Immunic, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 120.41 million compared to USD 92.95 million a year ago. Basic loss per share from continuing operations was USD 3.78 compared to USD 3.93 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.26 USD | -0.79% | +4.13% | -16.00% |
05-08 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.00% | 114M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022